{"disease":{"id":"lung-disease","name":"lung disease"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or functional or anatomical asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"fluticasone-furoate","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arnuity Ellipta","generic_name":"FLUTICASONE FUROATE","company_name":"Haleon Us Holdings","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":62,"revenue":"3100","mechanism":""},{"drug_id":"vilanterol","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Breo Ellipta","generic_name":"VILANTEROL","company_name":"Glaxo Grp Ltd","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":60,"revenue":"3100","mechanism":"Breo Ellipta works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"umeclidinium","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Incruse Ellipta","generic_name":"UMECLIDINIUM","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Anticholinergic","quality_score":70,"revenue":"3100","mechanism":"Umeclidinium works by blocking the M4 muscarinic acetylcholine receptor to relax airway smooth muscle and improve breathing."},{"drug_id":"nintedanib","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"glycopyrrolate","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glycopyrrolate","company_name":"Yonsei University","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"almitrine","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duxil","generic_name":"ALMITRINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"almitrine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"aclidinium-bromide","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tudorza Pressair","generic_name":"ACLIDINIUM BROMIDE","company_name":"Covis","drug_phase":"marketed","molecular_target":"M3 receptors, beta 2 -adrenergic receptors","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":"DUAKLIR PRESSAIR combines aclidinium, an anticholinergic, and formoterol, a beta 2 -adrenergic agonist, to provide bronchodilation in COPD."},{"drug_id":"ofev","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"ipratropium","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atrovent","generic_name":"IPRATROPIUM","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"oxitropium","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxytropium Bromide","generic_name":"OXITROPIUM","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"oxitropium","quality_score":null,"revenue":null,"mechanism":"Oxytropium works by blocking the action of acetylcholine, a neurotransmitter that causes airway muscles to contract."},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or alcoholism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"umec","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"UMEC","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":"UmeC is a small molecule drug that works by interacting with a specific target in the body."},{"drug_id":"incruse","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Incruse","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"brovana","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brovana","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-3 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vargatef","indication_name":"Systemic sclerosis associated interstitial lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"olodaterol","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Striverdi Respimat","generic_name":"OLODATEROL","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":55,"revenue":null,"mechanism":"Striverdi Respimat works by stimulating the beta-2 receptors in the lungs to relax airway muscles and improve breathing."},{"drug_id":"sialanar","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sialanar","company_name":"Proveca Pharma Limited","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"revefenacin","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yupelri","generic_name":"REVEFENACIN","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic [EPC]","quality_score":10,"revenue":null,"mechanism":"Yupelri works by blocking the action of a chemical called acetylcholine, which stimulates the muscles in the airways, leading to bronchodilation."},{"drug_id":"glycopyrronium-bromide","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cuvposa","generic_name":"GLYCOPYRRONIUM BROMIDE","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":62,"revenue":null,"mechanism":"Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body."},{"drug_id":"arformoterol","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brovana","generic_name":"ARFORMOTEROL","company_name":"Lupin","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":58,"revenue":null,"mechanism":"Brovana works by activating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic lung disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":26,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03225586","title":"Prospective Urban Rural Epidemiology Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT04489992","title":"Experiment on the Use of Innovative Computer Vision Technologies for Analysis of Medical Images in the Moscow Healthcare System","phase":"","overall_status":"UNKNOWN","enrollment_count":133000,"lead_sponsor_name":"Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department","has_results":false},{"nct_id":"NCT05957198","title":"Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease","phase":"","overall_status":"COMPLETED","enrollment_count":114921,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05253859","title":"CFTR Modulators and Gastrointestinal Complications","phase":"","overall_status":"COMPLETED","enrollment_count":47023,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT05875532","title":"Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":34960,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06679777","title":"Swedish CArdioPulmonary bioImage Study 2","phase":"","overall_status":"RECRUITING","enrollment_count":30154,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05681962","title":"Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University Magna Graecia","has_results":false},{"nct_id":"NCT06652776","title":"The Italian Registry of Patients With Chronic Obstructive Pulmonary Disease","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of Milan","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT06655090","title":"Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Dai Huaping","has_results":false},{"nct_id":"NCT06476470","title":"Taiwan Interstitial Lung Disease Multi-center Investigation and Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT07484243","title":"Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Yuanyuan Zhang","has_results":false},{"nct_id":"NCT05382572","title":"Pulmonary Fibrosis Foundation Community Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT05766046","title":"Lung Cancer Prevention Screening Programme in Italy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7324,"lead_sponsor_name":"Ugo Pastorino","has_results":false},{"nct_id":"NCT05244356","title":"Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation","phase":"NA","overall_status":"COMPLETED","enrollment_count":5784,"lead_sponsor_name":"Clinical Research Centre, Malaysia","has_results":false},{"nct_id":"NCT04048954","title":"Use of a Smartphone Application on the Detection of Complications Related to Smoking","phase":"","overall_status":"COMPLETED","enrollment_count":5671,"lead_sponsor_name":"Weprom","has_results":false},{"nct_id":"NCT04156594","title":"Preoperative Self-assessment for Cardio-pulmonary Risk Stratification","phase":"","overall_status":"COMPLETED","enrollment_count":5500,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT00014859","title":"Epidemiology of Surfactant Protein-B Deficiency","phase":"","overall_status":"COMPLETED","enrollment_count":5176,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT04190758","title":"GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5100,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT06577753","title":"REspiratory diSEAse cohoRt Studies of CHinese Medicine for ILD (RESEARCH-ILD)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05458934","title":"Analysis of Exhaled Breath From Patients With Lung-/Airway Diseases (BigExBrESs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT07070362","title":"Digital Early Warning System for Acute Lung Injury in Liver Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT03038698","title":"Paediatric and Adult African Spirometry II","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"University of KwaZulu","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT04370158","title":"Interstitial Lung Diseases Cohort Study in China","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT06036719","title":"Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04281784","title":"Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)","phase":"NA","overall_status":"COMPLETED","enrollment_count":2512,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT04896138","title":"University of Virginia Natural History Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2500,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT01443845","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2354,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03738202","title":"Multifaceted Intervention for Protection Against Cotton Dust Exposure Among Textile Workers","phase":"NA","overall_status":"COMPLETED","enrollment_count":2031,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT03901534","title":"Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD","phase":"NA","overall_status":"TERMINATED","enrollment_count":2021,"lead_sponsor_name":"Columbia University","has_results":true},{"nct_id":"NCT02758808","title":"Pulmonary Fibrosis Foundation Patient Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT02073708","title":"A Population-based Investigation of Asthma in the Telemark Region of Norway","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Sykehuset Telemark","has_results":false},{"nct_id":"NCT00001465","title":"Study of the Disease Process of Lymphangioleiomyomatosis","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT07080125","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05514522","title":"The UK Interstitial Lung Disease Long-COVID19 Study (UKILD-Long COVID): Understanding the Burden of Interstitial Lung Disease in Long COVID.","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04930289","title":"Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"Paragonix Technologies","has_results":false},{"nct_id":"NCT04503044","title":"ILAs in CT Lung Cancer Screening Population","phase":"","overall_status":"COMPLETED","enrollment_count":1703,"lead_sponsor_name":"Lahey Clinic","has_results":false},{"nct_id":"NCT05337163","title":"A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":1564,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07377864","title":"Clinical Characteristics and Immune Escape Mechanism of Nontuberculous Mycobacterial Lung Disease in South China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Eighth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT05810493","title":"A Cohort of Patients With Phenotyped Diffuse Interstitial Lung Disease With Longitudinal Follow-up","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06685874","title":"Interstitial Lung Disease Exacerbations Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Royal Devon and Exeter NHS Foundation Trust","has_results":false},{"nct_id":"NCT05855109","title":"Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors","phase":"","overall_status":"COMPLETED","enrollment_count":1304,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04501497","title":"Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)","phase":"","overall_status":"COMPLETED","enrollment_count":1221,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT06645977","title":"Patients With Interstitial Lung Disease","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05286918","title":"Antibiotic Stewardship in AECOPD Through CRP-Guided Management","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1184,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07126626","title":"Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1184,"lead_sponsor_name":"Gene Solutions","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}